Fiduciary Alliance LLC Raises Stock Position in United Therapeutics Corporation $UTHR

Posted by Stanley Muller on Jun 25th, 2026

Fiduciary Alliance LLC increased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 1,007.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,686 shares of the biotechnology company’s stock after acquiring an additional 6,082 shares during the quarter. Fiduciary Alliance LLC’s holdings in United Therapeutics were worth $3,862,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics during the third quarter worth $317,617,000. Norges Bank purchased a new stake in shares of United Therapeutics during the 4th quarter valued at $293,418,000. Avoro Capital Advisors LLC lifted its holdings in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR opened at $549.66 on Thursday. The firm has a market capitalization of $23.33 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 1.80 and a beta of 0.57. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company’s fifty day moving average price is $562.63 and its 200-day moving average price is $525.08.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the company earned $6.63 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.49 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $537.74, for a total value of $5,108,530.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $21,785,460.62. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $541.55, for a total value of $4,494,865.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,462,896.60. The trade was a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 633,718 shares of company stock worth $358,492,749. 8.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on UTHR. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. HC Wainwright boosted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

View Our Latest Report on UTHR

About United Therapeutics

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.